SubsidieMeestersRe-envisioning risk biomarkers in acute myeloid leukemia (AML) at single-cell level
The reMARK-AML project aims to refine prognostic risk parameters in NPM1-mutated acute myeloid leukemia by developing novel single-cell diagnostic assays for improved patient outcomes.
Projectdetails
Introduction
Acute myeloid leukemia (AML) is one of the most aggressive, clinically and biologically heterogeneous hematological malignancies. The different genetics classify disease entities and define the prognostic risk category to which AML patients are assigned and the treatment choices.
Genetic Classification
There is one entity, the AML with nucleophosmin (NPM1) gene mutations, that accounts for one-third of all adult AML (the most frequent). Another gene mutation, the Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD), acts as the tipping point for patient risk definition. This drastically worsens the prognosis and affects treatment in those 40% of patients where it is detected.
Research Background
This has been a main field of research for Prof. Maria Paola Martelli and her team for years, specifically through her ERC consolidator grant ContraNPM1AML. Here, she will exploit concepts stemming from her ERC-funded studies on the key role of kinases in the NPM1-mutated AML development, response to therapy, and initiating relapse.
Focus on Prognosis
The focus will be on the 60% of patients regarded as having a favorable prognosis, who nevertheless in 40% of cases will relapse with an extremely dismal outcome. Currently, successful strategies to identify novel frontline key markers to refine risk are not available.
Project Overview
reMARK-AML takes on the challenge of changing prognostic risk parameters, aiming to re-envision the marker at the single-cell level. A first strategy has been designed and will be tested for proof-of-concept in patients through a prospective non-interventional study.
Collaboration and Development
We have established contacts with industrial partners for the development of fit-for-purpose diagnostic assay prototypes to be tested in the study.
Future Challenges
The success of reMARK-AML will open the next challenge of developing marketable diagnostic kits and defining a strong business plan in order to measure the impact of our idea and proof-of-concept in the real-world clinical setting.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-8-2023 |
| Einddatum | 31-1-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI PERUGIApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PLASTicity of Endothelial Cell as new Target for acute myeloId leukemia TherapYThis project aims to investigate embryonic-like endothelial cells in acute myeloid leukemia to identify therapeutic targets that enhance treatment responses and improve patient outcomes. | ERC Starting... | € 1.499.000 | 2024 | Details |
Mechanistic models of leukemia-niche interaction using multimodal single cell profilingThis project aims to uncover AML's interactions with the bone marrow niche through advanced single-cell sequencing and modeling, potentially transforming treatment strategies for hematological malignancies. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Define a lead candidate for clinical development of a novel T cell therapyT2LEAD aims to develop and commercialize novel CAR T cell therapies targeting unique AML-specific antigens to improve treatment outcomes for acute myeloid leukemia patients. | ERC Proof of... | € 150.000 | 2023 | Details |
Decoding consequences of complex chromosomal aberrations by multi-modal single-cell deconstruction to overcome treatment-resistance cancerSHATTER-AML aims to unravel the genomic complexities of acute myeloid leukemia with complex karyotype through advanced single-cell analysis to develop targeted therapies against treatment resistance. | ERC Advanced... | € 2.499.375 | 2022 | Details |
Understanding Diagnosing and Early intervention in the Myeloid malignancy ContinuumThe Shlush lab aims to improve early diagnosis and treatment of myeloid malignancies by developing advanced diagnostic tools, exploring preleukemic mutations, and identifying targeted therapies. | ERC Consolid... | € 2.000.000 | 2025 | Details |
PLASTicity of Endothelial Cell as new Target for acute myeloId leukemia TherapY
This project aims to investigate embryonic-like endothelial cells in acute myeloid leukemia to identify therapeutic targets that enhance treatment responses and improve patient outcomes.
Mechanistic models of leukemia-niche interaction using multimodal single cell profiling
This project aims to uncover AML's interactions with the bone marrow niche through advanced single-cell sequencing and modeling, potentially transforming treatment strategies for hematological malignancies.
Define a lead candidate for clinical development of a novel T cell therapy
T2LEAD aims to develop and commercialize novel CAR T cell therapies targeting unique AML-specific antigens to improve treatment outcomes for acute myeloid leukemia patients.
Decoding consequences of complex chromosomal aberrations by multi-modal single-cell deconstruction to overcome treatment-resistance cancer
SHATTER-AML aims to unravel the genomic complexities of acute myeloid leukemia with complex karyotype through advanced single-cell analysis to develop targeted therapies against treatment resistance.
Understanding Diagnosing and Early intervention in the Myeloid malignancy Continuum
The Shlush lab aims to improve early diagnosis and treatment of myeloid malignancies by developing advanced diagnostic tools, exploring preleukemic mutations, and identifying targeted therapies.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
Ontwikkeling van innovatieve prognostische melanoomtestDit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing. | Mkb-innovati... | € 165.130 | 2020 | Details |
Bone Marrow-on-Chip as smart sensor of lung cancer relapseBuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival. | EIC Pathfinder | € 2.999.835 | 2024 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
Ontwikkeling van innovatieve prognostische melanoomtest
Dit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing.
Bone Marrow-on-Chip as smart sensor of lung cancer relapse
BuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.